These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18558256)

  • 21. Pramipexole extended release in Parkinson's disease.
    Hametner EM; Seppi K; Poewe W
    Expert Rev Neurother; 2011 Sep; 11(9):1229-34. PubMed ID: 21864066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
    Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
    Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease.
    Zavala JA; Munhoz RP; Teive HA
    J Clin Neurosci; 2012 Sep; 19(9):1298-9. PubMed ID: 22721884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of long-term levodopa therapy in malignant melanoma.
    Woofter MJ; Manyam BV
    Clin Neuropharmacol; 1994 Aug; 17(4):315-9. PubMed ID: 9316678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pramipexole: heart failure.
    Prescrire Int; 2013 Sep; 22(141):213. PubMed ID: 24171217
    [No Abstract]   [Full Text] [Related]  

  • 27. [A current view on dopamine receptor agonists in the treatment of Parkinson's disease].
    Titova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(9):76-83. PubMed ID: 26525820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pramipexole extended release: in Parkinson's disease.
    Chwieduk CM; Curran MP
    CNS Drugs; 2010 Apr; 24(4):327-36. PubMed ID: 20297857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postoperative hyperthermic syndrome following antiparkinsonian drugs withdrawal: the pitfall of enteral refeeding.
    Casier I; Jeanjean A; Hantson P
    Anaesth Intensive Care; 2013 Nov; 41(6):814-5. PubMed ID: 24180734
    [No Abstract]   [Full Text] [Related]  

  • 30. Neuroleptic malignant syndrome postoperative onset due to levodopa withdrawal.
    Young CC; Kaufman BS
    J Clin Anesth; 1995 Dec; 7(8):652-6. PubMed ID: 8747565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pramipexole-induced limb dystonia and its associated complex regional pain syndrome in idiopathic Parkinson's disease: A case report.
    Park D
    Medicine (Baltimore); 2017 Jul; 96(28):e7530. PubMed ID: 28700507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease.
    Sato Y; Asoh T; Metoki N; Satoh K
    J Neurol Neurosurg Psychiatry; 2003 May; 74(5):574-6. PubMed ID: 12700295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group.
    Ikebe S; Harada T; Hashimoto T; Kanazawa I; Kuno S; Mizuno Y; Mizuta E; Murata M; Nagatsu T; Nakamura S; Takubo H; Yanagisawa N; Narabayashi H
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S47-9. PubMed ID: 12735915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Severe leg edema associated with the use of dopaminergic drugs in Parkinson's disease. Report of one case].
    Miranda C M; Hudson A L
    Rev Med Chil; 2017 Dec; 145(12):1624-1625. PubMed ID: 29652961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials.
    Shen T; Ye R; Zhang B
    Eur J Neurol; 2017 Jun; 24(6):835-843. PubMed ID: 28480621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pramipexole-associated fixed limb dystonia in Parkinson's disease.
    Pandey S; Jain S
    Parkinsonism Relat Disord; 2016 Oct; 31():159-160. PubMed ID: 27591073
    [No Abstract]   [Full Text] [Related]  

  • 37. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
    Pinter MM; Rutgers AW; Hebenstreit E
    J Neural Transm (Vienna); 2000; 107(11):1307-23. PubMed ID: 11145006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preface: Malignant syndrome in Parkinson's disease.
    Narabayashi H; Mizuno Y
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S1. PubMed ID: 12735908
    [No Abstract]   [Full Text] [Related]  

  • 39. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions.
    Gerschlager W; Bloem BR
    Mov Disord; 2009 Sep; 24(12):1858-60. PubMed ID: 19514056
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.